ReviewLife (Basel, Switzerland)2024
Artificial Intelligence in the Non-Invasive Detection of Melanoma.
Review in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Use of artificial intelligence in analysis of endoscopic images to detect residual disease or regrowth in rectal patients with complete clinical response to neoadjuvant chemoradiotherapy.Techniques in coloproctology · 2026Article
- Automated triage of cancer-suspicious skin lesions with 3D total-body photography.NPJ digital medicine · 2025Article
- Comparative Dermoscopic Analysis of Melanoma In Situ Versus Thin Invasive Melanoma Considering BRAF Mutational Status.Journal of clinical medicine · 2025Article
- Advanced skin cancer prediction with medical image data using MobileNetV2 deep learning and optimized techniques.Scientific reports · 2025Article
- The Use of Artificial Intelligence for Skin Cancer Detection in Asia-A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- AI-Assisted Dermatology in Provider Shortage Areas: A Systematic Review of Access and Wait Time Outcomes.The Journal of clinical and aesthetic dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Skin cancer is one of the most prevalent cancers worldwide, with increasing incidence. Skin cancer is typically classified as melanoma or non-melanoma skin cancer. Although melanoma is less common than basal or squamous cell carcinomas, it is the deadliest form of cancer, with nearly 8300 Americans expected to die from it each year. Biopsies are currently the gold standard in diagnosing melanoma; however, they can be invasive, expensive, and inaccessible to lower-income individuals. Currently, suspicious lesions are triaged with image-based technologies, such as dermoscopy and confocal microscopy. While these techniques are useful, there is wide inter-user variability and minimal training for dermatology residents on how to properly use these devices. The use of artificial intelligence (AI)-based technologies in dermatology has emerged in recent years to assist in the diagnosis of melanoma that may be more accessible to all patients and more accurate than current methods of screening. This review explores the current status of the application of AI-based algorithms in the detection of melanoma, underscoring its potential to aid dermatologists in clinical practice. We specifically focus on AI application in clinical imaging, dermoscopic evaluation, algorithms that can distinguish melanoma from non-melanoma skin cancers, and in vivo skin imaging devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.